BC Extra | Jul 1, 2019
Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
BC Extra | Jun 17, 2016
Company News

Management tracks

Immunotherapy company Hookipa Biotech AG (Vienna, Austria) named Joern Aldag CEO. He was CEO of uniQure N.V. (NASDAQ:QURE). Cancer company Aprea AB (Solna, Sweden) named Christian Schade president and CEO. He was CEO of Novira...
BC Extra | Jan 27, 2016
Top Story

J&J rises after issuing 2016 guidance

Johnson & Johnson (NYSE:JNJ) gained $4.78 to $101.18 on Tuesday after reporting earnings and issuing 2016 guidance. The company expects adjusted EPS this year of $6.43-$6.58, exceeding a consensus estimate of $6.38. On a conference...
BC Extra | Jan 8, 2016
Company News

J&J announces 22 partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled 22 new collaborations spanning the cancer, diabetes, rare diseases and consumer healthcare sectors. The Innovation unit also said it will start an external...
BC Week In Review | Nov 9, 2015
Company News

Novira, J&J deal

Johnson & Johnson will acquire Novira for an undisclosed sum in a deal slated to close this quarter. Novira’s NVR 3-778 ( NVR-1221 ) is in Phase Ib testing to treat chronic HBV infection. Next half, the...
BC Extra | Nov 5, 2015
Company News

J&J acquiring Novira

Johnson & Johnson (NYSE:JNJ) will acquire HBV play Novira Therapeutics Inc. (Doylestown, Pa.) for an undisclosed sum. Novira's lead candidate NVR 3-778 ( NVR-1221 ) is in Phase I testing to treat chronic HBV infection. The compound...
BC Week In Review | Nov 24, 2014
Clinical News

NVR-1221: Phase Ia data

A Phase Ia trial in 40 healthy adults ages 18-65 showed that single oral doses of 50, 150, 400 and 800 mg NVR-1221 and twice-daily doses of 200 mg NVR-1221 for 14 days were well...
BC Extra | Oct 18, 2014
Company News

VC tracks

Canaan Partners promoted Tim Shannon to general partner and Julie Papanek to principal on the healthcare team. Shannon joined Canaan in 2009 after serving as CEO of CuraGen Corp. through its sale to Celldex Therapeutics...
BC Week In Review | Sep 22, 2014
Clinical News

NVR-1221: Phase Ib started

Novira began a 2-part, double-blind, placebo-controlled, international Phase Ib trial of once- or twice-daily NVR-1221 in up to 96 patients. The first part will evaluate NVR-1221 as monotherapy in up to 48 patients, while the...
Items per page:
1 - 10 of 20
BC Extra | Jul 1, 2019
Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
BC Extra | Jun 17, 2016
Company News

Management tracks

Immunotherapy company Hookipa Biotech AG (Vienna, Austria) named Joern Aldag CEO. He was CEO of uniQure N.V. (NASDAQ:QURE). Cancer company Aprea AB (Solna, Sweden) named Christian Schade president and CEO. He was CEO of Novira...
BC Extra | Jan 27, 2016
Top Story

J&J rises after issuing 2016 guidance

Johnson & Johnson (NYSE:JNJ) gained $4.78 to $101.18 on Tuesday after reporting earnings and issuing 2016 guidance. The company expects adjusted EPS this year of $6.43-$6.58, exceeding a consensus estimate of $6.38. On a conference...
BC Extra | Jan 8, 2016
Company News

J&J announces 22 partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled 22 new collaborations spanning the cancer, diabetes, rare diseases and consumer healthcare sectors. The Innovation unit also said it will start an external...
BC Week In Review | Nov 9, 2015
Company News

Novira, J&J deal

Johnson & Johnson will acquire Novira for an undisclosed sum in a deal slated to close this quarter. Novira’s NVR 3-778 ( NVR-1221 ) is in Phase Ib testing to treat chronic HBV infection. Next half, the...
BC Extra | Nov 5, 2015
Company News

J&J acquiring Novira

Johnson & Johnson (NYSE:JNJ) will acquire HBV play Novira Therapeutics Inc. (Doylestown, Pa.) for an undisclosed sum. Novira's lead candidate NVR 3-778 ( NVR-1221 ) is in Phase I testing to treat chronic HBV infection. The compound...
BC Week In Review | Nov 24, 2014
Clinical News

NVR-1221: Phase Ia data

A Phase Ia trial in 40 healthy adults ages 18-65 showed that single oral doses of 50, 150, 400 and 800 mg NVR-1221 and twice-daily doses of 200 mg NVR-1221 for 14 days were well...
BC Extra | Oct 18, 2014
Company News

VC tracks

Canaan Partners promoted Tim Shannon to general partner and Julie Papanek to principal on the healthcare team. Shannon joined Canaan in 2009 after serving as CEO of CuraGen Corp. through its sale to Celldex Therapeutics...
BC Week In Review | Sep 22, 2014
Clinical News

NVR-1221: Phase Ib started

Novira began a 2-part, double-blind, placebo-controlled, international Phase Ib trial of once- or twice-daily NVR-1221 in up to 96 patients. The first part will evaluate NVR-1221 as monotherapy in up to 48 patients, while the...
Items per page:
1 - 10 of 20